Docoh
Loading...

SLNO Soleno Therapeutics

APP
Utility
Methods for Treating Subjects with Prader-willi Syndrome or Smith-magenis Syndrome
21 Oct 21
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels.
Neil M. COWEN
Filed: 25 Nov 20
GRANT
Utility
Resuscitation bag
20 Jul 21
Resuscitation apparatuses and methods for assisted ventilation are described herein.
Constantine Andrew Gillespie, Otho Newman Boone, Pedro E. De La Serna, Anthony D. Wondka
Filed: 2 Dec 16
GRANT
Utility
Salts of potassium ATP channel openers and uses thereof
29 Jun 21
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels.
Neil M. Cowen, Khaled A. Yamout
Filed: 11 Nov 19
GRANT
Utility
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
28 Dec 20
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels.
Neil M. Cowen
Filed: 16 Sep 19
APP
Utility
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
29 Jul 20
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels.
Neil Madison COWEN
Filed: 21 Nov 19
APP
Utility
Salts of Potassium Atp Channel Openers and Uses Thereof
15 Jul 20
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels.
Neil M. COWEN, Khaled A. YAMOUT
Filed: 10 Nov 19
APP
Utility
Methods for Treating Subjects with Prader-willi Syndrome or Smith-magenis Syndrome
13 May 20
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels.
Neil M. COWEN
Filed: 16 Sep 19
  • 1
Patents are sorted by USPTO publication date, most recent first